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Results.– Among the 52 patients treated 64% were male, 37% are children aged
5 to 15 years. Hemiplegia and cerebral palsy represent 73% of diseases treated.
The equine foot was treated in 54% of cases where a percentage of 64% muscle
toxins represented by the triceps surae (42% of gastrocnemius, soleus 21%).
Before treatment, the mean VAS pain was 6.85, the average Ashworth was 3.1,
the mean range of motion (dorsiflexion of the ankle) was 78. After treatment,
the mean VAS pain increased to 4.02 that of Ashworth 2, and the mean joint
amplitudes increased to 1.58.
Discussion.– The results obtained after injection of botulinum toxin in these 52
patients were satisfactory standard analgesic, hypertonic and joint mobility, by a
regression of pain intensity estimated at three points on average, a regression
point of the spasticity and a gain of passive joint movement of 8.58 on average.
These results have led to an improvement in the lives of patients at the
functional level with an average of 53.63% EVA satisfaction.
Conclusion.– Focal spasticity is causing functional impairment of a major
source of pain and muscle-tendon and articular use of botulinum toxin has
dramatically improved the lives of these 52 patients, hence the interest to
generalize this method therapeutic.
http://dx.doi.org/10.1016/j.rehab.2012.07.826
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Aim.– To establish if patients reporting unusual fatigue present generalized
diffusion of BoNTA. Fatigue after BoNTA injection is frequently reported in
literature (up to 18% of injected patients).
Material and methods.– Retrospective, monocentric study. Generalized
diffusion has been searched with s ingle fiber EMG (or Neuromuscular Jitter)
on striated muscles away from BoNTA injected muscles. Neuromuscular jitter
(NMJ) is compared between 16 patients with unusual fatigue after BoNTA
injection, 17 asymptomatic patients treated with BoNTA (control group), 19
patients suffering botulism-like syndrome having muscular deficit distant from
BoNTA injection site and three patients suffering botulism food poisoning.
Indications were treatment of neurogenic detrusor overactivity or spasticity.
NMJ is the gold standard for evaluating neuromuscular junction dysfunction.
Mean jitter, percentage of pathological fibers and number of conduction blocks
are compared between groups.
Results.– Mean jitter, percentage of pathologic fibers and conduction blocks for
asymptomatic patients differs from those of patients presenting distant muscular
deficit (P = 0.0001) and patients suffering botulism (P = 0.017). Mean jitter and
number of conduction blocks differs between patients presenting unusual
fatigue and patients presenting distant muscular deficit (P = 0.0005). No
significant difference appears between asymptomatics and patients relating
unusual fatigue after BoNTA treatment.
Discussion.– This study doesn’t give rise to generalized BoNTA diffusion in
patients reporting unusual fatigue after BoNTA treatment although jitter clearly
differs between patients presenting distant muscle weakness and control group.
Generalized neuromuscular disorder doesn’t seem to explain those fatigue
events. Several hypotheses can account for it: not enough patients in the group
reporting unusual fatigue, fatigue could be due to autonomic nervous system
disorder that is not explored with this single fiber EMG, immune mechanism.
Fatigue could be reported to initial disease.
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Objective.– Over the past few years, several studies have shown that a
botulinum toxin (BTX-A) injection in the rectus femoris muscle (RF) could
enhance stroke patients’ walking capacity (Robertson et al., 2009). However,
the mechanisms behind these benefits are still unknown. The aim of this study
was to compare the analytical effect of BTX-A in the RF muscle (passive stretch
and voluntary strength assessed by an isokinetic dynamometer) and functional
repercussions on gait (assessed by three-dimensional motion analysis) in spastic
hemiparetic patients with stiff knee gait (SKG) caused by RF spasticity.
Methods.– Ten stroke patients with SKG caused by RF spasticity were included
and evaluated before and after a BTX-A injection in RF. Analytical evaluations
consisted of: (i) a clinical examination; (ii) an assessment using an isokinetic
dynamometer with surface electromyography (in order to quantify passive
stretch and knee flexor and extensor voluntary strength; (iii) a three-dimensional
motion analysis gait assessment (in order to quantify spatiotemporal and
kinematic gait parameters).
Results.– One month after BTX-A injection in RF, the following results were
found: (i) a decrease in knee extensor strength and an increase in knee flexor
strength; (ii) no change in the intensity of extensor activity during passive
stretch; (iii) an increase in the angle at which the stretch reflex occurred. 3D
analyses showed an increase in gait speed, which was related to an increase in
cadence and an increase in peak knee flexion during swing phase.
Discussion.– The improvement in knee flexion following BTX-A injection in
RF seems to be related to an increase in the angle at which the stretch reflex
occurs with no change in intensity of the contraction. This change in the
threshold of the sensitivity of neuromuscular spindles infers that BTX-A affects
the motoneuron g-neuromuscular spindle synapse (Trompetto et al., 2006).
http://dx.doi.org/10.1016/j.rehab.2012.07.828
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Background.– An understanding of the mechanical effects of botulinum toxin
types A (BoNTA) on spastic and voluntary muscle contraction may help predict
functional responders.
Objective.– To compare the effect of BoNTA on voluntary and stretch reflex-
related torque (and angle at peak torque) produced by activation of the rectus
femoris (RF) muscle.
Methods.– A prospective open pilot study. n = 15 incomplete SCI patients,
impaired by a specific RF spasticity (n = 20), with RF hyperactivity in mid-
swing and a stiff-knee-gait quantified by formal Gait Analysis (GA), were
assessed before and after BoNTA injection (Botox, 200 UI). Main outcome
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